A Phase 1, Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of MRTX849 in Chinese Patients With Advanced Solid Tumors With KRAS G12C Mutation
Latest Information Update: 01 Mar 2023
At a glance
- Drugs Adagrasib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors ZAI Lab
Most Recent Events
- 23 Feb 2023 Planned primary completion date changed from 31 Oct 2022 to 31 Oct 2023.
- 09 Nov 2022 Planned End Date changed from 31 Oct 2022 to 31 Oct 2023.
- 09 Nov 2022 Status changed from recruiting to active, no longer recruiting.